Published in Gut on January 03, 2014
Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection (BEEPER) | NCT03427346
ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol (2015) 3.22
Endoscopic treatments for dysplastic Barrett's esophagus: resection, ablation, what else? World J Surg (2015) 1.46
Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. Gastrointest Endosc (2014) 1.41
Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus: a systematic review and meta-analysis. Endosc Int Open (2017) 0.81
Advances in the management of Barrett's esophagus and early esophageal adenocarcinoma. Gastroenterol Rep (Oxf) (2015) 0.77
Optimizing the diagnosis and therapy of Barrett's esophagus. J Thorac Dis (2017) 0.75
Evolving management of metaplasia and dysplasia in Barrett's epithelium. World J Gastroenterol (2016) 0.75
The Barrett's Gland in Phenotype Space. Cell Mol Gastroenterol Hepatol (2014) 0.75
Low grade dysplasia in Barrett's esophagus: Should we worry? World J Gastrointest Pathophysiol (2014) 0.75
Impact of reassessment of colonic hyperplastic polyps by expert GI pathologists. Int J Colorectal Dis (2016) 0.75
Endoscopic treatment for dysplastic Barrett's esophagus. World J Surg (2015) 0.75
Neoplastic Barrett's oesophagus and long-term follow-up after endoscopic therapy: complete histological eradication of Barrett associated with high-grade dysplasia significantly decreases neoplasia relapse. Surg Endosc (2016) 0.75
Ablation Therapy for Barrett's Esophagus: New Rules for Changing Times. Curr Gastroenterol Rep (2017) 0.75
Endoscopic detection of proximal serrated lesions and pathologic identification of sessile serrated adenomas/polyps vary on the basis of center. Clin Gastroenterol Hepatol (2013) 2.37
Management of recurrent symptoms after per-oral endoscopic myotomy in achalasia. Gastrointest Endosc (2017) 1.96
Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncol (2016) 1.40
Use of modified multiband ligator facilitates circumferential EMR in Barrett's esophagus (with video). Gastrointest Endosc (2006) 1.01
Clinical response to peroral endoscopic myotomy in patients with idiopathic achalasia at a minimum follow-up of 2 years. Gut (2015) 0.96
Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma. Gut Liver (2016) 0.83
Supportive evidence for FOXP1, BARX1, and FOXF1 as genetic risk loci for the development of esophageal adenocarcinoma. Cancer Med (2015) 0.81
Expert opinions and scientific evidence for colonoscopy key performance indicators. Gut (2016) 0.77
Endoscopic mucosal resection of large colorectal adenomas: Only for expert centers? United European Gastroenterol J (2015) 0.77
Early adverse events of per-oral endoscopic myotomy. Gastrointest Endosc (2016) 0.77
The Barrett-associated variants at GDF7 and TBX5 also increase esophageal adenocarcinoma risk. Cancer Med (2016) 0.76
Lectin Histochemistry Shows WGA, PHA-L and HPA Binding Increases During Progression of Human Colorectal Cancer. Anticancer Res (2015) 0.76
A novel prepless X-ray imaging capsule for colon cancer screening. Gut (2015) 0.76
Prevention of hemolytic uremic syndrome with daily bowel lavage in patients with Shiga toxin-producing enterohemorrhagic Escherichia coli O104:H4 infection. JAMA Intern Med (2014) 0.75
Recovery of endoscopy services in the era of COVID-19: recommendations from an international Delphi consensus. Gut (2020) 0.75
Minimally invasive and endoscopic versus open necrosectomy for necrotising pancreatitis: a pooled analysis of individual data for 1980 patients. Gut (2017) 0.75